Anna Ljung

Anna Ljung has a diverse work experience in the pharmaceutical and biotechnology industries. Anna began their career as the Chief Financial Officer of Moberg Pharma AB in 2006 and held the position until 2019. In 2019, they transitioned to become the Chief Executive Officer of Moberg Pharma AB, a role they currently hold.

In addition to their work with Moberg Pharma AB, Anna Ljung is also involved in other companies. Anna is the Chairman of the board at OncoZenge, a Swedish pharmaceutical company focused on developing better products for supportive care of cancer patients. Anna has held this role since 2020.

Anna Ljung is also a Board Member of Saniona, a clinical-stage biopharmaceutical company. Saniona specializes in discovering and developing innovative rare disease treatments. Anna has held this position since 2018.

Furthermore, Anna Ljung is a Board Member of ADDvise Group AB, a leading supplier of equipment and services to healthcare and research facilities. Anna joined the board in 2022.

Earlier in their career, Anna Ljung served as the Chief Financial Officer of Athera Biotechnologies AB and as a Business Controller at Lipopeptide AB. Anna also has entrepreneurial experience as the Founder of Ideas of Sweden and Bright Brush AB.

Overall, Anna Ljung has extensive experience in executive and board-level positions in the pharmaceutical and biotechnology industries, with a focus on drug delivery and rare diseases.

From 2000 to 2005, Anna Ljung attended the Stockholm School of Economics, where they pursued a Master's degree in Economics and Business Administration.